• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/9/21 3:14:59 PM ET
    $AERI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AERI alert in real time by email
    SC 13G 1 tm215817d12_sc13g.htm SC 13G

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 13G* 

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT 

    TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED 

    PURSUANT TO § 240.13d-2 

    (Amendment No. )*

     

    Aerie Pharmaceutical Inc. 

    (Name of Issuer)
     
    Common Stock
    (Title of Class of Securities)
     
    00771V108
    (CUSIP Number)
     
    12/31/2020
    (Date of Event Which Requires Filing of the Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

     

    The Hartford Mutual Funds, Inc. on behalf of:

    The Hartford Midcap Fund and Hartford Small Company Fund 

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     ¨

    (b)     ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Maryland 

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

     

     

    6.

     

    SHARED VOTING POWER

     

    0

     

    7.

     

    SOLE DISPOSITIVE POWER

     

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    0 

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0 

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%

     

    12.

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IV

     

     

     

    Item 1(a). Name of Issuer:
     

     

    Aerie Pharmaceutical Inc.

       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
     

    4301 Emperor Blvd., Suite 400

    Durham, NC 27703 

       
    Item 2(a). Name of Person Filing:
       
      The Hartford Mutual Funds, Inc. on behalf of:
    The Hartford Midcap Fund and Hartford Small Company Fund
       
    Item 2(b). Address of Principal Business Office or, if none, Residence:
       
      690 Lee Road
    Wayne, PA 19087
       
    Item 2(c). Citizenship:
       
      Maryland
       
    Item 2(d). Title of Class of Securities:
       
      Common Stock
       
    Item 2(e). CUSIP Number:
     

     

    00771V108

       
    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
       
      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) x Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
      (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
      (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.

     

     

     

     

    Item 4. Ownership:
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       
      (a) Amount beneficially owned:  0
         
      (b) Percent of class: 0%
         
      (c) Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote:
           
        (ii)

    Shared power to vote or to direct the vote:

     

    0

           
        (iii) Sole power to dispose or to direct the disposition of:
           
        (iv)

    Shared power to dispose or to direct the disposition of:

     

    0

           
    Item 5. Ownership of Five Percent or Less of a Class:
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following. x
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person: N/A
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company: N/A
       
    Item 8. Identification and Classification of Members of the Group: N/A
       
    Item 9. Notice of Dissolution of Group: N/A
       
    Item 10. Certifications:
       
      By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Date: February 9, 2021
         
      By: /s/ Joseph. G Melcher
         
      Name:  
         
      Title: Chief Compliance Officer

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, Provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations 

    (see 18 U.S.C. 1001).

     

     

     

    Get the next $AERI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AERI

    DatePrice TargetRatingAnalyst
    8/29/2022$14.00 → $15.25Buy → Neutral
    Citigroup
    8/23/2022Buy → Hold
    Needham
    8/23/2022$30.00 → $15.25Overweight → Neutral
    Cantor Fitzgerald
    2/25/2022$22.00 → $14.00Buy
    Needham
    11/5/2021$24.00 → $22.00Buy
    Needham
    8/5/2021$26.00 → $24.00Buy
    Needham
    More analyst ratings

    $AERI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Mchugh Julie returned $245,449 worth of shares to the company (16,095 units at $15.25), closing all direct ownership in the company to cover taxes

      4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)

      11/21/22 4:59:15 PM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Mcgraw Benjamin F Iii returned $640,256 worth of shares to the company (41,984 units at $15.25), closing all direct ownership in the company to satisfy tax liability

      4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)

      11/21/22 4:57:44 PM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Mcdonnell Peter J returned $121,924 worth of shares to the company (7,995 units at $15.25), closing all direct ownership in the company (for withholding tax)

      4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)

      11/21/22 4:56:06 PM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AERI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company's Ophthalmic Pharmaceutical Business

      Leveraging Alcon's robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Alcon's presence in the $20 billion global ophthalmic pharmaceutical category1 Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has completed its acquisition of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI, "Aerie"))). This transaction helps bolster Alcon's presence in the ophthalmic pharmaceutical space with its growing portfolio of commercial products and development pi

      11/22/22 1:01:00 AM ET
      $AERI
      $ALC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Ophthalmic Goods
    • Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results

      Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the third quarter ended September 30, 2022. "Aerie delivered another solid performance in the third quarter and executed well across our three strategic pillars of growth. Our first-in-class glaucoma franchise showed strong continued year-over-year growth, in line with our expect

      11/3/22 4:01:00 PM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment Options

      Webinar to be held Friday, September 23, 2022 @ 10 a.m. ET Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced that it will host a Key Opinion Leader (KOL) webinar on Friday, September 23, 2022 from 10:00 a.m. – 11:30 a.m. Eastern Time. The event will feature Dr. Laura Periman, MD, of the Periman Eye Institute, and Dr. John Sheppard, MD, of the Virginia Eye Consultants, who will discuss New Perspectives on Dry Eye Disease (DED), including the Current Landscape, Unmet Medical Needs, and Emerging Treatment Options, including Aerie's investigational TRPM8 agoni

      9/13/22 8:00:00 AM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AERI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aerie Pharma downgraded by Citigroup with a new price target

      Citigroup downgraded Aerie Pharma from Buy to Neutral and set a new price target of $15.25 from $14.00 previously

      8/29/22 7:08:38 AM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aerie Pharma downgraded by Needham

      Needham downgraded Aerie Pharma from Buy to Hold

      8/23/22 8:56:43 AM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aerie Pharma downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded Aerie Pharma from Overweight to Neutral and set a new price target of $15.25 from $30.00 previously

      8/23/22 7:09:23 AM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AERI
    SEC Filings

    See more

    $AERI
    Financials

    Live finance-specific insights

    See more

    $AERI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $AERI
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form 15-12G filed by Aerie Pharmaceuticals Inc.

      15-12G - AERIE PHARMACEUTICALS INC (0001337553) (Filer)

      12/1/22 3:07:11 PM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Aerie Pharmaceuticals Inc.

      S-8 POS - AERIE PHARMACEUTICALS INC (0001337553) (Filer)

      11/21/22 11:55:29 AM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Aerie Pharmaceuticals Inc.

      S-8 POS - AERIE PHARMACEUTICALS INC (0001337553) (Filer)

      11/21/22 11:52:52 AM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company's Ophthalmic Pharmaceutical Business

      Leveraging Alcon's robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Alcon's presence in the $20 billion global ophthalmic pharmaceutical category1 Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has completed its acquisition of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI, "Aerie"))). This transaction helps bolster Alcon's presence in the ophthalmic pharmaceutical space with its growing portfolio of commercial products and development pi

      11/22/22 1:01:00 AM ET
      $AERI
      $ALC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Ophthalmic Goods
    • Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results

      Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the third quarter ended September 30, 2022. "Aerie delivered another solid performance in the third quarter and executed well across our three strategic pillars of growth. Our first-in-class glaucoma franchise showed strong continued year-over-year growth, in line with our expect

      11/3/22 4:01:00 PM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio

      Builds on Alcon's existing commercial expertise in the estimated $20 billion global ophthalmic pharmaceutical segment1 Adds Rocklatan® and Rhopressa®, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical product candidates Transaction values Aerie at approximately $770 million in equity value and is expected to be accretive to Alcon's core diluted EPS in 2024 Ad hoc announcement pursuant to Art. 53 LR Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and Aerie Pharmaceuticals, Inc. (NASDAQ:AERI, "Aerie"))), a pharmaceutical company focused on the discovery, development, manufacturing and commercialization of first-in

      8/22/22 9:18:00 PM ET
      $AERI
      $ALC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Ophthalmic Goods
    • SEC Form SC 13G/A filed by Aerie Pharmaceuticals Inc. (Amendment)

      SC 13G/A - AERIE PHARMACEUTICALS INC (0001337553) (Subject)

      2/10/23 10:00:04 AM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Aerie Pharmaceuticals Inc. (Amendment)

      SC 13G/A - AERIE PHARMACEUTICALS INC (0001337553) (Subject)

      11/10/22 4:06:40 PM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Aerie Pharmaceuticals Inc. (Amendment)

      SC 13G/A - AERIE PHARMACEUTICALS INC (0001337553) (Subject)

      2/14/22 12:39:59 PM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer

      Finance executive with a successful track record in capital creation, deployment, and optimization Brings breadth of finance, strategy and business development experience Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Peter F. Lang will join the Company as Chief Financial Officer, effective March 18, 2022. He will report to Raj Kannan, Chief Executive Officer of Aerie Pharmaceuticals and become a member of the Aerie Executive Committee. "I am pleased to welcome Peter to our leadership team," said Raj Kannan, Chief Executive Officer. "His extensive e

      3/18/22 7:00:00 AM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aerie Pharmaceuticals Appoints Gary Sternberg, M.D., M.B.A. as Chief Medical Officer

      Fellowship-trained Ophthalmologist and well-rounded biopharmaceutical executive brings breadth of clinical development, medical affairs, strategy, and business development experience Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Gary Sternberg, M.D., M.B.A., will join the Company as Chief Medical Officer (CMO), effective March 1, 2022. He will report to Raj Kannan, Chief Executive Officer of Aerie Pharmaceuticals and become a member of the Aerie Executive Committee. Gary is an Ophthalmologist who is fellowship trained in cornea and external disease

      2/24/22 6:30:00 AM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer

      An accomplished leader Brings a depth and breadth of commercial, business development, and portfolio strategy experience Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today announced that Raj Kannan will join the Company as Chief Executive Officer and a director, effective December 20, 2021. "On behalf of the Board of Directors, I am very pleased to welcome Raj Kannan to Aerie. During the search process, the Board was pleased to interview several strong candidates and Raj rose to the top of the list during the process. Raj brings a track record of building effective organizations and teams, launching and growing products in the U.S. and globally, buildi

      12/16/21 6:30:00 AM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care